Journal of Gastroenterology

, Volume 47, Issue 9, pp 941–960

Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances

  • Tetsuhide Ito
  • Hisato Igarashi
  • Robert T. Jensen
Review

DOI: 10.1007/s00535-012-0642-8

Cite this article as:
Ito, T., Igarashi, H. & Jensen, R.T. J Gastroenterol (2012) 47: 941. doi:10.1007/s00535-012-0642-8
  • 785 Downloads

Abstract

Neuroendocrine tumors (NETs) [carcinoids, pancreatic neuroendocrine tumors (pNETs)] are becoming an increasing clinical problem because not only are they increasing in frequency, but they can frequently present with advanced disease that requires diagnostic and treatment approaches different from those used in the neoplasms that most physicians are used to seeing and treating. In the past few years there have been numerous advances in all aspects of NETs including: an understanding of their unique pathogenesis; specific classification systems developed which have prognostic value; novel methods of tumor localization developed; and novel treatment approaches described. In patients with advanced metastatic disease these include the use of newer chemotherapeutic approaches, an increased understanding of the role of surgery and cytoreductive methods, the development of methods for targeted delivery of cytotoxic agents, and the development of targeted medical therapies (everolimus, sunitinib) based on an increased understanding of the disease biology. Although pNETs and gastrointestinal NETs share many features, recent studies show they differ in pathogenesis and in many aspects of diagnosis and treatment, including their responsiveness to different therapies. Because of limited space, this review will be limited to the advances made in the management and treatment of patients with advanced metastatic pNETs over the past 5 years.

Keywords

Neuroendocrine tumorPancreatic endocrine tumorLiver metastasesGastrinomaInsulinomaSurgeryChemotherapyStreptozotocinEverolimusSunitinibSomatostatinOctreotideLanreotideHepatic transarterial embolizationLiver transplantationPeptide receptor radionuclide therapySomatostatin receptorSIRTChemoembolizationUnresectable liver metastases

Abbreviations

ACTHomas

ACTH-secreting pancreatic neuroendocrine tumors

CNS

Central nervous system

ENETS

European Neuroendocrine Tumor Society

ESMO

European Society for Medical Oncology

GI

Gastrointestinal

GI-NETs

Gastrointestinal neuroendocrine tumors (carcinoids of gastrointestinal tract)

TAE/TACE

Transarterial embolization/chemoembolization

IGF

Insulin-like growth factor

UICC/AJCC/WHO

International Union for Cancer Control/American Joint Cancer Committee/World Health Organization

MRI

Magnetic resonance imaging

NANETS

North American Neuroendocrine Tumor Society

NCCN

National Comprehensive Cancer Network

NETs

Neuroendocrine tumors (carcinoids, pancreatic neuroendocrine tumors)

NF-pNETs

Nonfunctional pancreatic neuroendocrine tumors

pNETs

Pancreatic neuroendocrine tumors

PDGFRs

Platelet-derived growth factor receptors

PRRT

Peptide receptor radionuclide therapy

RFA

Radiofrequency ablation

SIRT

Selective internal radiation

SRS

Somatostatin receptor scintigraphy

VEGFR

Vascular endothelial growth factor receptor

VIPomas

Vasoactive intestinal peptide-secreting pancreatic neuroendocrine tumors

Copyright information

© Springer (outside the USA) 2012

Authors and Affiliations

  • Tetsuhide Ito
    • 1
  • Hisato Igarashi
    • 1
  • Robert T. Jensen
    • 2
  1. 1.Department of Medicine and Bioregulatory Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Digestive Diseases BranchNIDDK, NIHBethesdaUSA